Tumor cell viability

Tumor cell viability refers to the proportion of live, functional cells within a malignant cell population and serves as a fundamental phenotypic readout in oncology research. It is not a specific molecular target, such as a receptor or enzyme, but rather a physiological state representing the integrated outcome of various cellular processes including metabolism, membrane integrity, and proliferative capacity (NIH Assay Guidance Manual, 2013). In drug discovery, measuring tumor cell viability is the primary method for assessing the cytotoxic or cytostatic efficacy of potential anti-cancer agents, often quantified through the half-maximal inhibitory concentration (IC50). Common laboratory assays evaluate viability by measuring intracellular ATP levels, mitochondrial enzymatic activity, or the integrity of the plasma membrane (Nature Education, 2014). While reducing tumor cell viability is the ultimate goal of most cancer therapies, this effect is achieved by modulating specific molecular drivers rather than the viability 'target' itself. Consequently, viability is considered a biomarker of drug effect or a screening endpoint rather than a therapeutic target in the traditional pharmacological sense.

Other names

Cancer cell viabilityCell survivalCellular viabilityTumor cell proliferation

Not applicable as this is a phenotypic outcome or biological state rather than a specific molecular target.